IFE is an independent international research foundation for energy and nuclear technology. IFE’s mandate is to undertake research and development, on an ideal basis and for the benefit of society, within renewable energy and environmental technology, oil and gas, nuclear medicine and nuclear safety, and to carry out assignments in the field of nuclear technology for the nation.
IFE was founded in 1948 as The Institute for Atomic Energy (IFA). IFA developed into Norway’s largest research institute, and in 1980 IFA changed its name to the Institute for Energy Technology – IFE. Since that time, the institute has further developed and become a leading international, experimental research institute.
IFE has about 600 employees with headquarters at Kjeller, and research activities at Kjeller and Halden.
IFE’s vision is to be an internationally leading energy research institute.
Every year one to two percent of Norway’s population undergoes a medical assessment using radioactive pharmaceutical products. The isotope laboratories at IFE are the Norwegian control organ for radioactive medicines. The laboratories are organized as a pharmacy and provide advice and guidance on the use of the products. The majority of radioactive medicines used in Norway are controlled at IFE before they are sent out to Norwegian hospitals.
The isotope Laboratories at IFE has significant expertise and know-how across the entire product development chain supported by experienced staff in radiochemistry and radiopharmacy.
IFE has dedicated laboratories for production, packaging and quality control of radiopharmaceuticals. These laboratories are classified in respect of cleanliness classes in accordance with international GMP (Good Manufacturing Practice) rules and in accordance with radiation protection legislation.
IFE has facilities and licenses for global distribution of radiopharmaceuticals for clinical and commercial phase.
IFE is a Contract Research Organization (CRO) for production of new radiopharmaceuticals. In addition IFE is a Contract Manufacturing Organization (CMO). IFE has a dedicated manufacturing line for the contract manufacturing of Xofigo (a radiopharmaceutical based on the radioisotope Ra-223 and developed by Algeta in Norway). Xofigo has been manufactured by IFE for global supply since May 2013. IFE is also performing contract analyses.
In addition IFE has facilities to conduct research with isotopes including production of new isotopes.